RESUMEN
Regenerative treatment of dilated, non-ischaemic cardiomyopathy represents a significant unmet clinical need. Intracoronary administration of autologous bone marrow stem cells has demonstrated positive results in treatment of post-infarct and chronic ischaemic patients. Limitations of this procedure include: invasiveness of bone marrow extraction and cardiac catheterization, and dependence on stem cell populations that are aged and possibly senescent. Here, the use of intravenously administered allogeneic placental matrix derived mesenchymal stem cells for treatment of dilated cardiomyopathy is discussed. Safety of this cell population has already been established in completed Phase I and II trials; however, to date, clinical implementation for dilated cardiomyopathy has not been reported. Preclinical studies have demonstrated that mesenchymal stem cells: (i) inhibit myocardial inflammation; (ii) inhibit cardiomyocyte apoptosis; (iii) stimulate angiogenesis; and (iv) display therapeutic activity in models of dilated cardiomyopathy. Clinical studies have demonstrated the ability of mesenchymal stem cells to inhibit post-infarct remodelling, as well as potently block inflammatory processes in graft versus host and Crohn disease. Presented here is case report of a patient with dilated cardiomyopathy treated with intravenous allogeneic mesenchymal stem cells and expanded umbilical cord blood CD34 cells who underwent a profound clinical improvement.
Asunto(s)
Cardiomiopatía Dilatada/terapia , Trasplante de Células Madre de Sangre del Cordón Umbilical , Trasplante de Células Madre Mesenquimatosas , Antígenos CD34/metabolismo , Trasplante de Médula Ósea , Cardiomiopatía Dilatada/metabolismo , Femenino , Insuficiencia Cardíaca/terapia , Humanos , Mediadores de Inflamación/metabolismo , Persona de Mediana Edad , Placenta/citología , Células Madre/metabolismoRESUMEN
Autism spectrum disorders (ASD) are a group of neurodevelopmental conditions whose incidence is reaching epidemic proportions, afflicting approximately 1 in 166 children. Autistic disorder, or autism is the most common form of ASD. Although several neurophysiological alterations have been associated with autism, immune abnormalities and neural hypoperfusion appear to be broadly consistent. These appear to be causative since correlation of altered inflammatory responses, and hypoperfusion with symptology is reported. Mesenchymal stem cells (MSC) are in late phases of clinical development for treatment of graft versus host disease and Crohn's Disease, two conditions of immune dysregulation. Cord blood CD34+ cells are known to be potent angiogenic stimulators, having demonstrated positive effects in not only peripheral ischemia, but also in models of cerebral ischemia. Additionally, anecdotal clinical cases have reported responses in autistic children receiving cord blood CD34+ cells. We propose the combined use of MSC and cord blood CD34+cells may be useful in the treatment of autism.
Asunto(s)
Trastorno Autístico/terapia , Trasplante de Células Madre/métodos , Animales , Trastorno Autístico/inmunología , Encéfalo/patología , Trasplante de Células Madre de Sangre del Cordón Umbilical , Humanos , Inmunomodulación , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/inmunologíaRESUMEN
De julio 1993 a febrero 1994 se estudió la presencia de Listeria spp. en 220 muestras de leche cruda recolectadas directamente en tanques de almacenamiento de lecherías seleccionadas aleatoriamente en el área metropolitana, San José, Costa Rica. Las muestras fueron analizadas con la metodología recomendada por la International Dairy Federation. Se aisló Listeria spp. de 14 (6.4 per cent) de las muestras, el 45 per cent de las cepas fue L. innocua, el 1.4 per cent L. welshimeri y el 0.5 per cent L. gravi. No se aisló L. monocytogenes. Tampoco se determinaron variaciones estacionales en la presencia de esta bacteria
